

Mortality and loss to follow up before initiation of antiretroviral therapy among HIV-infected children eligible for HIV treatment

Gerardo Alvarez-Uria, Praveen Kumar Naik, Manoranjan Midde, Raghavakalyan Pakam

Department of Infectious Diseases, Rural Development Trust Hospital, Bathalapalli, AP, India

Abstract

Data on attrition due to mortality or loss to follow-up (LTFU) from antiretroviral therapy (ART) eligibility to ART initiation of HIVinfected children are scarce. The aim of this study is to describe attrition before ART initiation of 247 children who were eligible for ART in a cohort study in India. Multivariable analysis was performed using competing risk regression. The cumulative incidence of attrition was 12.6% (95% confidence interval, 8.7-17.3) after five years of follow-up, and the attrition rate was higher during the first months after ART eligibility. Older children (>9 years) had a lower mortality risk before ART initiation than those aged <2 years. Female children had a lower risk of LTFU before ART initiation than males. Children who belonged to scheduled tribes had a higher risk of delayed ART initiation and LTFU. Orphan children had a higher risk of delayed ART initiation and mortality. Children who were >3 months in care before ART eligibility were less likely to be LTFU. The 12-month risk of AIDS, which was calculated using the absolute CD4 cell count and age, was strongly associated with mortality. A substantial proportion of ART-eligible children died or were LTFU before the initiation of ART. These findings can be used in HIV programmes to design actions aimed at reducing the attrition of ART-eligible children in India.

Introduction

In the absence of any intervention, over half of children infected with human immune-deficiency virus (HIV) die by the second year of life.¹ Antiretroviral therapy (ART) reduces the mortality risk by 75%,² but only 28% of children who are eligible for ART are receiving it.³ Consequently, there is an urgent need to increase the uptake of ART among children living with HIV, especially in low or middleincome countries.³ Typically, the preparation of HIV infected children eligible for ART requires several counselling sessions on the part of the caregivers, before ART is started.⁴ During this period, children may drop out. Studies from low and middle-income countries have shown that 25% of adults in need of HIV treatment die or are lost to follow up (LTFU) before starting ART.^{5,6} However, data on the attrition of ARTeligible children, especially outside sub-Saharan Africa, is scarce.⁷

India has the highest burden of paediatric HIV in Asia.⁸ Of the 112,385 children registered in ART centres by December 2012, only 34,367 (30.6%) had started ART.⁸ A better understanding of the attrition process before ART initiation is essential to design effective strategies to increase the uptake of ART among HIVinfected children in India. The objective of this study is to describe the proportion of ART-eligible children who started ART in a cohort study in India. In particular, we aimed to find predictors of mortality and LTFU before ART initiation, which could help HIV programmes to design actions intended to reduce the attrition from care of HIV-infected children in India.

Materials and Methods

Setting and design

The study was performed in Anantapur, a district situated in the south border of Andhra Pradesh, India. Anantapur has a population of approximately four million people of which 72% live in rural areas.⁹ The HIV epidemic in Anantapur is largely driven by heterosexual transmission and is characterized by poor socio-economic conditions and high levels of illiteracy.¹⁰ Rural Development Trust (RDT) is a non-governmental organization that provides free-of-charge medical care to HIV-infected people, including medicines, consultations, and hospital admission charges.

The Vicente Ferrer HIV Cohort Study (VFHCS) is an open cohort study of all HIV infected patients who have attended RDT hospitals. The characteristics of the cohort have been described in detail elsewhere.^{10,11} For this study, we selected HIV infected children (<15 years old) from the VFHCS who became eligible for ART between January 1st 2007 and July 15th 2013. ART eligibility was defined by immunological criteria (CD4 count <1500 cells/µL or <25% in children aged <12 months, CD4 count <750 cells/µL or <20% in children aged 12-35 months, CD4 count <350 cells/µL or <15% in children aged 36-59 months, and CD4 count <350 cells/µL in children aged >59 months) according to the Indian National Guidelines.4

Key words: India, HIV, lost to follow-up, antiretroviral therapy, elegibility determination.

Contributions: GAU contributed to the study concept and design, analysis, and manuscript preparation; PKN contributed to data acquisition, and manuscript preparation; MM contributed to data acquisition, and manuscript preparation; RK contributed to data acquisition, and manuscript preparation.

Conflict of interests: the authors declare no potential conflict of interests.

Received for publication: 11 Novembe 2013. Revision received: 12 December 2013. Accepted for publication: 20 December 2013.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright G. Alvarez-Uria et al., 2014 Licensee PAGEPress, Italy Infectious Disease Reports 2014; 6:5167 doi:10.4081/idr.2014.5167

Definitions

The designation of the patients' community was self-reported. The scheduled caste community is marginalised in the traditional Hindu caste hierarchy and, therefore, suffers from social and economic exclusion and disadvantage. In general the scheduled tribe (ST) community is geographically isolated with limited economic and social contact with the rest of the population. Backward castes form a series of intermediate castes that were considered low in the traditional caste hierarchy, but above scheduled castes.¹² Patients were considered as living near a town when they lived in a mandal (administrative subdivision of districts in Andhra Pradesh; e.g., Anantapur District has 64 mandals) including a town with a population >100,000 people. For children with both parents alive, parents were asked whether they lived in a rented house or in an owned house, as a marker of the economical conditions for the caregivers.

In HIV infected children <5 years, the CD4 lymphocyte percentage has been generally preferred for monitoring the immune status because of the variability of the CD4 cell count during the first years of life.¹³ However, an analysis of the HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) demonstrated that the CD4 percentage provides little or no additional prognostic value compared with the CD4 cell count in children.¹⁴ Therefore, the immune status of children was calculated using the 12-month risk of AIDS adopted in the HPPMCS, which is based on the CD4 cell count and the age of children to calculate the level of immunodeficiency.¹⁵ Because of the small number of older children included in the HPPMCS, children >12 years were recorded as if they were 12 years old to calculate the 12-month AIDS risk.¹⁶

Statistical analysis

Statistical analysis was performed with Stata Statistical Software (Stata Corporation. Release 11. College Station, Texas, USA). To investigate predictors of ART initiation, mortality and LTFU, time-to-event methods were used. Time was measured from the date of ART eligibility to ART initiation or death, whichever occured first.17 Children who did not die nor started ART were recorded at the last visit date. Children who did not come to the clinics for at least 180 days after their last visit date were considered LTFU.¹⁸ Cox regression models assume that the distribution of censoring times and the time-to-event distribution are independent of each other.¹⁹ When studying the cumulative incidence of ART initiation, a group of children will be censored at death or at the last visit date. However, dead children will not be able to start ART and LTFU children have a higher probability of not starting ART than those who come regularly to the clinics.²⁰ The inclusion of these children in standard survival models may lead to an overestimation of the proportion of children who start ART. Thus, multivariable analysis and estimation of the cumulative incidence of ART initiation, mortality and LTFU were performed using competing risk proportional hazard models taking the other events of interest as competing events.21 These models estimate sub-distribution hazard ratios (SHRs), which can be interpreted similarly to hazard ratios estimated by Cox proportional models, but they take into account the hazard of the competing events.¹⁹ The cumulative incidence of ART initiation, mortality and LTFU were estimated using the stcompet command in Stata.22,23 The study was approved by the Ethical Committee of the RDT Institutional Review Board.

Results

We identified 247 children from the VFHCS who met the inclusion criteria. The study included 1452 child-months and, during the study, 195 started ART, 10 children died and 20 were LTFU. Among children who were LTFU, the median time of follow-up was 2.8 months [interquartile range (IQR), 0.4-12.5; mean 8.4 months] and, the median time from ART eligi-

bility to ART initiation was 0.95 months (IQR, 0.16-3.2). Among children who died, the median time from ART eligibility to death was 1.2 months (IQR, 0.07-9.2).

Baseline characteristics at time of ART eligibility and the multivariable analysis of factors associated with ART initiation, mortality and LTFU are described in Table 1. The median age was 6.74 years (IOR, 3-10.14), over half were female, over half belonged to BC communities, 60% were living far from a town and 27% lived near the hospital. Near half of the children had lost one or both of their parents, and the majority of those with parents alive were living in a rented house. Three quarters of children became ART eligible within three months from entry into care. Taking into account the age and the CD4 lymphocyte count, the median estimated 12-month risk of AIDS was 6.77% (IOR 4-17.34, range 2.75-75.2). Older children (>9 years) had a lower risk of mortality than those aged <2 years. Female children had a lower risk of LTFU than males. Children who belonged to ST communities had a higher risk of delayed ART initiation and LTFU. Children who lived near a town had a higher risk of LTFU. Compared to orphan children, children who lost only their mother had a lower risk of delayed ART initiation and mortality. Children who lost only their father had also a lower risk of death than orphan children. Children who were >3 months in the programme before ART eligibility were less likely to be LTFU. The 12-month risk of AIDS was strongly associated with mortality, since a 1% increase of the 12-month risk of AIDS was associated with a 4% increase in the risk of mortality. Raw and adjusted SHRs for these



variables are presented in Table 1.

A stacked graph of the status of HIV-infected children since ART eligibility is presented in Figure 1. The cumulative incidence of children who started ART was 59.1% (95% CI, 52.6-64.9) at 3 months, 64.5% (95% CI, 58.1-70.1) at 6 months, 72.9% (95% CI, 66.8-78.1) at 1 year, 78.3% (95% CI, 72.4-83.1) at 2 years, and 82.2% (95% CI. 76.3-86.8) at 3 years. The cumulative incidence of attrition (mortality or LTFU) before ART initiation was 7.3% (95% CI, 4.5-11) at 3 months, 7.7% (95% CI, 4.8-11.5) at 6 months, 9.5% (95% CI, 6.2-13.6) at 1 year, 10.4% (95% CI, 7-14.7) at 2 years, and 12.6% (95% CI, 8.7-17.3) at 3 years. At 3 years, the cumulative incidence of mortality and LTFU was 3.8% (95% CI, 1.9-6.7) and 8.9% (95% CI, 5.6-13.1), respectively.

Discussion

The results of this study show that approximately 13% of ART eligible children die or are LTFU before starting ART. This proportion is substantially smaller than the proportion of ART eligible adults who are lost-to-programme before ART initiation described in a metaanalysis study in sub-Saharan Africa,⁵ which was 24.6% (95% CI, 18.8-30.3). The median time from ART eligibility to ART initiation was less than one month, which is considerably shorter than in studies from sub-Saharan Africa and Cambodia.^{24.26} The proportion of children who started ART was similar in Ivory Coast, Lesotho and Zambia (70-86%),^{27.29} but higher than the ones reported in studies from



Figure 1. Stacked graph describing the cumulative incidence of antiretroviral therapy (ART) initiation and attrition in 247 ART-eligible children in Anantapur, India.



Gambia and South-Africa (33-40%).24,30

To our knowledge, this is the first study that describes the risk factors of attrition among ART eligible children in India. In accordance with previous studies, 1,24,29 children aged <2years have a higher risk of mortality than older children. In line with studies from sub-Saharan Africa,^{31,32} orphan children have a higher risk of mortality suggesting that they are more vulnerable than children who have at least one of their parents. In contrast with studies from sub-Saharan Africa,24,28 we found significant gender differences. While there is a trend towards higher mortality in female children, male children are more likely to become LTFU. Children who belonged to ST communities have a higher risk of delayed ART initiation and LTFU, indicating that these children should be followed up until ART is started, and their caregivers may need extra-support and counselling. The risk of LTFU is significantly higher in children who have become ART eligible within three months of inclusion in the program, indicating that paediatric ART programmes should put more emphasis on the follow-up of children who become ART eligible soon after entering into care.

Children with higher levels of immunodeficiency are more likely to die before initiating ART and the mortality is concentrated in the first months after ART eligibility. These findings are in accordance with the studies conducted in the Ivory Coast and Gambia,^{24,28} suggesting that strategies to ensure earlier diagnosis, prompt inclusion and timely initiation of ART could be effective in reducing the mortality of HIV-infected children living in the developing countries.³³

The study has some limitations. Children who are LTFU might not be lost forever, since

they may be included again at a later time or in other HIV centres. Children who lived near a town might have been more likely to attend other ART centres near their homes after their caregivers knew they needed to start ART. However, studies performed in adults have demonstrated a high mortality in LTFU patients,³⁴ as was observed also in a study on children conducted in Western Kenya.³⁵

Conclusions

In our setting, 13% of ART eligible children are lost-to-program before ART initiation. Children who are orphans or belong to ST communities need extra support, because they are at higher risk of attrition. Male children and children who become ART eligible soon after

Table 1. Baseline characteristics and raw and multivariable analysis of factors associated with antiretroviral therapy (ART) initiation,
mortality and loss to follow up of 247 children eligible for ART in Anantapur, India.

	N (%)	ART initiation SHR aSHR		Mortality SHR aSHR		Loss to follow up SHR aSHR	
		- Onk				<u>- 511K</u>	
Age (years) 0-2	69 (27.94)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
3-4	38 (15.38)	0.78 (0.48-1.27)	0.75 (0.45-1.23)	0.74 (0.14-3.92)	0.92 (0.09-9.84)	1.03 (0.30-3.51)	0.76 (0.14-4.02)
5-9	70 (28.34)	1.13 (0.77-1.65)	1.07 (0.67-1.70)	0.56 (0.14-2.27)	1.29 (0.22-7.55)	0.67 (0.21-2.08)	0.85 (0.24-2.92)
>9	70 (28.34)	1.52* (1.04-2.21)	1.29 (0.81-2.04)	0.00* (0.00-0.00)	0.00* (0.00-0.00)	0.55 (0.16-1.88)	0.43 (0.07-2.42)
Gender							
Female	115 (46.56)	0.87 (0.66-1.15)	0.89 (0.66-1.19)	2.72 (0.71-10.41)		0.48 (0.19-1.25)	0.32* (0.13-0.80)
Male	132 (53.44)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
Community	10 (10 10)		0.00 (0.00 1.00)		0 50 (0 00 10 40)		
OC DC	48 (19.43)	0.91 (0.66-1.25)	0.90 (0.63-1.28)		0.58 (0.02-19.43)	2.17 (0.49-9.57)	3.37 (0.72-15.70)
BC SC	139 (56.28) 47 (19.03)	1 (Reference) 0.94 (0.60-1.45)	1 (Reference) 0.82 (0.49-1.37)	1 (Reference)	1 (Reference) 4.02 (0.15-107.36)	1 (Reference) 1.56 (0.26-9.22)	1 (Reference) 1.00 (0.13-7.85)
ST	13 (5.26)	$0.34(0.00^{-1.45})$ $0.33^*(0.12^{-0.87})$	$0.37^* (0.14-0.97)$			7.41* (1.25-43.80)	9.24* (1.02-83.46)
Living near a town		()	()			()	(
No	149 (60.32)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
Yes	98 (39.68)	0.83 (0.63-1.11)	0.82 (0.60-1.13)	0.36 (0.08-1.66)	0.38 (0.07-2.08)	2.90* (1.16-7.24)	4.48* (1.11-18.02)
Time to ART centre							
<30 min	67 (27.13)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
>30 min	180 (72.87)	1.19 (0.86-1.63)	1.15 (0.79-1.68)	0.85 (0.22-3.28)	0.34 (0.10-1.10)	0.85 (0.33-2.21)	2.16 (0.58-8.09)
Year of ART eligibility							
<2009	62 (25.1)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
2009	43 (17.41)	0.99 (0.68-1.44)	0.95 (0.62-1.46)	0.49 (0.05-4.59)	1.09 (0.09-12.52)	1.10 (0.24-5.00)	1.63 (0.26-10.03)
2010	55 (22.27)	0.66 (0.43-1.03)	0.75 (0.48-1.18)	0.39 (0.04-3.72)	0.40 (0.02-9.79)	2.56 (0.80-8.22)	3.35* (1.12-10.05)
2011 2012	43 (17.41) 44 (17.81)	$\begin{array}{c} 0.92 \ (0.62 - 1.36) \\ 0.77 \ (0.51 - 1.18) \end{array}$	$\begin{array}{c} 0.88 \ (0.57-1.36) \\ 0.81 \ (0.51-1.28) \end{array}$	0.50 (0.05-4.74) 2.19 (0.53-8.97)	$\begin{array}{c} 0.62 \ (0.06-5.96) \\ 3.84 \ (0.41-36.32) \end{array}$	$\begin{array}{c} 1.12 \ (0.25\text{-}5.04) \\ 0.38 \ (0.04\text{-}3.39) \end{array}$	$\begin{array}{c} 1.47 \ (0.28-7.56) \\ 0.50 \ (0.07-3.81) \end{array}$
	(11.01)	0.11 (0.01-1.10)	0.01 (0.01-1.20)	2.13 (0.55-0.51)	5.04 (0.11-50.52)	0.00 (0.04-0.00)	0.00 (0.01-0.01)
Status of parents Alive, rented house	71 (28.74)	0.49* (0.32-0.75)	0.65 (0.40-1.06)	1.17 (0.23-5.91)	0.41 (0.05-3.65)	3.18 (0.73-13.91)	3.92 (0.69-22.30)
Alive, owned house	55 (22.27)	0.70 (0.44-1.09)	0.88 (0.55-1.41)	1.16 (0.21-6.46)	0.32 (0.06-1.81)	0.36 (0.03 - 3.96)	0.39 (0.03-4.32)
Father died	64 (25.91)	0.90 (0.59-1.37)	1.17 (0.73-1.87)	0.32 (0.03-3.37)	0.08* (0.01-0.44)	1.65 (0.33-8.34)	2.23 (0.37-13.44)
Mother died	18 (7.29)	1.43 (0.81-2.53)	1.81* (1.06-3.10)	0.00* (0.00-0.00)	0.00* (0.00-0.00)	1.14 (0.10-12.96)	2.91 (0.16-53.07)
Both died	39 (15.79)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
Pre-ART care							
<3 months	185 (74.9)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
>3 months	62 (25.1)	0.68* (0.50-0.93)	0.74 (0.53-1.02)	1.34 (0.35-5.13)	1.00 (0.25-4.01)	0.33 (0.08-1.40)	0.19* (0.05-0.78)
12-month AIDS risk (%) *P <0.05; °median (interguartile r	6.8 (4-17.3)°	1.00 (0.99-1.01)	1.00 (0.99-1.01)	1.04* (1.02-1.07)	· /	1.01 (0.98-1.03)	1.01 (0.97-1.05)

*P <0.05; °median (interquartile range). aSHR, adjusted sub-distribution hazard ratio; ART, antiretroviral, therapy; BC, backward castes; CI, confidence interval; N, number; OC, other castes; SHR, sub-distribution hazard ratio; SC, scheduled castes; ST, scheduled tribes.

inclusion in the program are more likely to be LTFU and, therefore, they should be followedup with utmost attention. The results of this study can be used in HIV program to design actions aimed at reducing the attrition of HIVinfected children before the initiation of ART in India.

References

- 1. Newell M-L, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-43.
- 2. Edmonds A, Yotebieng M, Lusiama J, et al. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med 2011;8:e1001044.
- 3. UNAIDS. 2012 UNAIDS report on the global AIDS epidemic. Available from: http://www.unaids.org/en/media/unaids/con tentassets/documents/epidemiology/2012/gr 2012/20121120_UNAIDS_Global_Report_20 12_en.pdf
- 4. National AIDS Control Organisation. Guidelines for HIV care and treatment in infants and children. 2006. Available from: http://www.nacoonline.org/NACO/About_NA CO/Policy__Guidelines/Policies__Guidelin esl/
- Mugglin C, Estill J, Wandeler G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2012; 17:1509-20.
- Alvarez-Uria G, Pakam R, Midde M, Naik PK. Predictors of delayed antiretroviral therapy initiation, mortality, and loss to followup in HIV infected patients eligible for HIV treatment: data from an HIV cohort study in India. Biomed Res Int 2013;849042.
- 7. Mugglin C, Wandeler G, Estill J, et al. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review. PLoS ONE 2013; 8:e56446.
- National AIDS Control Organisation. India. HIV estimates 2012. Technical report. 2013. Available from: www.nacoonline.org/upload/ Surveillance/Reports%20&%20Publication/ T e c h n i c a 1 % 2 0 R e p o r t % 2 0 -%20India%20HIV%20 Estimates% 202012. pdf
- 9. Office of The Registrar General and Census Commissioner, India. Census of India. 2011.
- 10. Alvarez-Uria G, Midde M, Pakam R, Naik PK. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of

adults and children in an HIV cohort from a rural district of India. Infect Dis Rep 2012;4:e19.

- 11. Alvarez-Uria G, Midde M, Pakam R, et al. Factors associated with late presentation of HIV and estimation of antiretroviral treatment need according to CD4 lymphocyte count in a resource-limited setting: data from an HIV cohort study in India. Interdiscip Perspect Infect Dis 2012;2012:293795.
- 12. Alvarez-Uria G, Midde M, Naik PK. Sociodemographic risk factors associated with HIV infection in patients seeking medical advice in a rural hospital of India. J Public Health Res 2012;1:e14.
- World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010. Available from: http://www.who.int/hiv/ pub/paediatric/infants2010/en/index.html.
- 14. HIV Paediatric Prognostic Markers Collaborative Study, Boyd K, Dunn DT, et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010;24:1213-7.
- 15. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006;20:1289-94.
- 16. HPPMCS. Estimating risk of disease progression in HIV-infected children. Available from: http://www.hppmcs.org/.
- Fox MP, Larson B, Rosen S. Defining retention and attrition in pre-antiretroviral HIV care: proposals based on experience in Africa. Trop Med Int Health 2012;17:1235-44.
- Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011;8:e1001111.
- 19. Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS 2010;24:2717-25.
- 20. Geng EH, Bwana MB, Muyindike W, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr 2013;63:e64-71.
- 21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
- 22. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004;4:103-12.
- 23. Cleves MA, Gould WW, Gutierrez RG. An introduction to survival analysis using Stata. College Station: Stata Corp; 2008.

- 24. Okomo U, Togun T, Oko F, et al. Mortality and loss to programme before antiretroviral therapy among HIV-infected children eligible for treatment in The Gambia, West Africa. AIDS Res Ther 2012;9:28.
- 25. Raguenaud M-E, Isaakidis P, Zachariah R, et al. Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatr 2009;9:54.
- 26. Sutcliffe CG, van Dijk JH, Bolton-Moore C, et al. Differences in presentation, treatment initiation, and response among children infected with human immunodeficiency virus in urban and rural Zambia. Pediatr Infect Dis J 2010;29:849-54.
- 27. Sutcliffe CG, van Dijk JH, Munsanje B, et al. Risk factors for pre-treatment mortality among HIV-infected children in rural Zambia: a cohort study. PLoS One 2011;6:e29294.
- 28. Anaky M-F, Duvignac J, Wemin L, et al. Scaling up antiretroviral therapy for HIVinfected children in Côte d'Ivoire: determinants of survival and loss to programme. Bull World Health Organ 2010;88:490-9.
- 29. Leyenaar JK, Novosad PM, Ferrer KT, et al. Early clinical outcomes in children enrolled in human immunodeficiency virus infection care and treatment in lesotho. Pediatr Infect Dis J 2010;29:340-5.
- 30. Feucht UD, Kinzer M, Kruger M. Reasons for delay in initiation of antiretroviral therapy in a population of HIV-infected South African children. J Trop Pediatr 2007;53:398-402.
- Ntanda H, Olupot-Olupot P, Mugyenyi P, et al. Orphanhood predicts delayed access to care in Ugandan children. Pediatr Infect Dis J. 2009;28:153-5.
- 32. Vreeman RC, Wiehe SE, Ayaya SO, et al. Association of antiretroviral and clinic adherence with orphan status among HIVinfected children in Western Kenya. J Acquir Immune Defic Syndr 2008;49:163-70.
- 33. Alvarez-Uria G, Pakam R, Midde M, Naik PK. Entry, retention, and virological suppression in an HIV cohort study in India: description of the cascade of care and implications for reducing HIV-related mortality in low- and middle-income countries. Interdiscip Perspect Infect Dis 2013;2013:384805.
- Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009;4:e5790.
- 35. Nyandiko W, Vreeman R, Liu H, et al. Nonadherence to clinic appointments among HIV-infected children in an ambulatory care program in western Kenya. J Acquir Immune Defic Syndr 2013;63:e49-55.



